| A novel triple mix radiobinding assay for the three ZnT8 (ZnT8-RWQ) autoantibody variants in children with newly diagnosed diabetes. | |
| | |
MedLine Citation:
|
PMID: 21708156 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND AND AIMS: Autoantibodies against the zinc transporter 8 (ZnT8A) are common in type 1 diabetes (T1D). ZnT8A analyses are complicated by the fact that there are three variants of the autoantigen at amino acid position 325 representing ZnT8-R (Arginine), ZnT8-W (Tryptophan) and ZnT8-Q (Glutamin). The aims of the study were: 1) to develop an autoantigen triple mix Radio-Binding Assay (RBA) for ZnT8A; 2) to identify the individual ZnT8-R,-W,-QA reactivity and 3) to validate the triple mix ZnT8A RBA in children with newly diagnosed T1D. METHODS: Serum samples were obtained from 2664 (56% males, n=1436) patients in the Swedish nationwide Better Diabetes Diagnosis (BDD) study representing patients with T1D (97%, n=2582), T2D (1.7%, n=46), MODY (1.0%, n=28) and secondary diabetes (0.3%, n=8). cDNA coding for the C-terminal end of each variant was prepared by site-directed mutagenesis and subcloned into a high efficiency in vitro transcription translation vector. The ZnT8 variants were labeled with 35S-methionine and used in a standard RBA separating free from autoantibody-bound autoantigen with Protein A-Sepharose. RESULTS: ZnT8-TripleA was detected in 1678 (65%) patients with T1D, 4 (9%) T2D, 3 (11%) MODY and in none (0%) of the patients with secondary diabetes. Among the T1D patients ZnT8-RA was detected in 1351 (52%) patients, ZnT8-WA in 1209 (47%) and ZnT8-QA in 790 (31%) demonstrating that 1661 (64%) had one or several ZnT8A. The ZnT8-TripleA assay showed a false positive rate of 1.9% (n=49). Only 1.2% (n=32) of the T1D patients were false negative for ZnT8-TripleA compared to 0/46 (0%) of the T2D patients. The precision (intra assay CV) and reproducibility (inter assay CV) of the ZnT8-TripleA assay did not differ from the RBA of the individual ZnT8 variants. CONCLUSION: We conclude that the ZnT8-TripleA assay had low false positive and false negative rates. The ZnT8-TripleA assay would therefore be highly suitable not only to analyze patient with newly diagnosed diabetes but also for screening the general population since this assay demonstrated high sensitivity and very high specificity. |
| | |
Authors:
|
Fariba Vaziri-Sani; Ahmed J Delli; Helena Elding-Larsson; Bengt Lindblad; Annelie Carlsson; Gun Forsander; Sten A Ivarsson; Johnny Ludvigsson; Claude Marcus; Ake Lernmark |
Related Documents
:
|
15524316 - Insulin resistance and abomasal motility disorders in cows detected by use of abomasodu... 8730616 - Effects of bifidobacterium sp fermented milk ingested with or without inulin on colonic... 9915886 - Iron is well absorbed by healthy adults after ingestion of double-fortified (iron and d... 20113186 - Relationship between serum ferritin and inflammatory biomarkers with insulin resistance... 17628816 - Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: ... 6704016 - Argon laser-induced cataract. a clinicopathologic study. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-6-24 |
Journal Detail:
|
Title: Journal of immunological methods Volume: - ISSN: 1872-7905 ISO Abbreviation: - Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-6-28 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 1305440 Medline TA: J Immunol Methods Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier B.V. All rights reserved. |
Affiliation:
|
Department of Clinical Sciences, Lund University, Malmö, Sweden. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Binding of RhoA by the C2 domain of E3 ligase Smurf1 is essential for Smurf1-regulated RhoA ubiquiti...
Next Document: Immunoradiometric assay for human serum amyloid P component.